|Boston Scientific Launches Precision Spectra™; Warner Chilcott Announces FDA Approval of DORYX(R)|
|By Staff and Wire Reports|
|Friday, 12 April 2013 18:46|
Boston Scientific Corporation (NYSE: BSX) has received approval by the U.S. FDA and is beginning a limited launch of the Precision Spectra Spinal Cord Stimulator (SCS) System. The Precision Spectra System is the world's first and only SCS system with Illumina 3D™ software and 32 contacts, and is designed to provide improved pain relief to a wide range of patients who suffer from chronic pain. Boston Scientific, the United States market leader in rechargeable SCS devices exiting 2012, is introducing the system at the annual meeting of the American Academy of Pain Medicine in Fort Lauderdale, Florida. Images of the Precision Spectra System can be downloaded here.
More than 100 million Americans suffer from chronic pain. Living in constant pain for an extended period of time can have a devastating impact on quality of life for many patients. Without relief, or the hope for relief, many patients lose the ability to sleep, work and function normally.
Spinal cord stimulators deliver electrical pulses from an implantable pulse generator to leads with stimulating contacts in order to mask pain signals traveling to the brain. The Precision Spectra System features Illumina 3D software designed to improve control of the stimulation field. The software is based on a proprietary computer model that takes into account 3D anatomical structures, including the conductivity of the spinal cord and surrounding tissue. The physician simply selects a desired location on the spinal cord and the programming software creates a customized stimulation field to mask the patient's pain.
Warner Chilcott plc (Nasdaq: WCRX) announced the U. S. FDA has approved a 200 mg strength of DORYX® (doxycycline hyclate) Delayed-Release Tablets. DORYX Delayed-Release Tablets are a tetracycline-class oral antibiotic. The Company anticipates that it will commercially launch DORYX Delayed-Release 200 mg Tablets in July 2013.
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, will report financial results for the first quarter 2013 on Tuesday, May 7, 2013, after the close of the market.
BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTC BB: BRTX), a life sciences company focused on stem cell based cellular therapies for various personal medical applications, announced today that it will implement a one-for-fifty reverse stock split effective at the opening of business on April 15, 2013.
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) and ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc. announced today that they have entered into a new merger agreement pursuant to which an acquisition subsidiary of BioSante will merge into ANI.
Elan Corporation, plc (NYSE: ELN) announces that, at an Extraordinary General Meeting (EGM) held earlier today, the sole ordinary resolution to approve the Tender Offer to purchase Ordinary Shares (including Ordinary Shares represented by American Depositary Shares) was overwhelmingly passed with over 99% of the shares voted in favor of the resolution.
Ingen Technologies, Inc.'s (PINKSHEETS: IGNT) is pleased to announce that on April 11, 2013 the company and ATMC Inc. have finalized the negotiations and anticipate signing the Purchase and Agreement of Acquisition early next week.
Life Technologies Corporation (NASDAQ: LIFE) today announced the acquisition of KDR Biotech Co., Ltd., (KDR Biotech) a leading reagents distributor based in Seoul, Korea.
OrbiMed Advisors LLC (“OrbiMed”) today announced that Glass Lewis & Co., a leading provider of corporate governance services to institutional shareholders, has recommended that shareholders of 3SBio (SSRX:NASDAQ) vote AGAINST the company’s going-private acquisition by a consortium of buyers that includes the company’s Chairman and CEO and other senior executives.
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) reported today that it has received approval from the U.S. Food and Drug Administration (“FDA”) for its New Drug Application (“NDA”) Topicort® (desoximetasone) Topical Spray, 0.25%.
XenoPort, Inc. (Nasdaq: XNPT) reported today that GlaxoSmithKline (GSK), who holds commercialization rights to Horizant® (gabapentin enacarbil) Extended-Release Tablets in the United States during a transition period ending on April 30, 2013, has experienced manufacturing delays that have resulted in a stockout of Horizant.